Related Experiment Video
Updated: Jun 4, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Molecular Diversity of Embryonic-Type Neuroectodermal Tumors Arising From Testicular Germ Cell Tumors
Yang Zong1, Rongrong Huang2, Mireille Bitar3
1Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California; Now with Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
Abstract:
Embryonic-type neuroectodermal tumors (ENTs) arising from testicular germ cell tumors (GCTs) are a relatively common type of somatic transformation in GCTs with poor prognosis and limited therapeutic options, particularly when patients develop disease recurrence or metastasis. Knowledge of key events driving this transformation is limited to the paucity of comprehensive genomic data. We performed a retrospective database search in a Clinical Laboratory Improvement Amendments- and College of American Pathologists-certified laboratory for testicular GCT-derived ENTs that had previously undergone next-generation sequencing-based comprehensive genomic profiling during the course of clinical care. Clinicopathological and genomic data were centrally rereviewed. Here, we report the molecular features of 10 ENTs of testicular GCT origin. All tumors harbored gain of chromosome 12p, often with KRAS, CCND2, and KMD5A coamplification, supporting a germ cell origin. The tumors were microsatellite-stable and exhibited a low tumor mutational burden. Three tumors (30%) exhibited MYCN or MYC amplification with co-occurring inactivation of the p53 pathway via either TP53 mutations or MDM2 amplification in 2 tumors. Three additional tumors (30%) had activation of the PI3K pathway via PIK3CA and PIK3CG mutations or PIK3C2B amplification; 1 tumor with co-occurring CDK4 amplification. Gene rearrangements were detected in 3 tumors (30%), with novel BRD4::MAU2 and BCOR::CLIP2 fusions as well as an internal truncating ATRX rearrangement, respectively. In summary, ENTs arising from GCTs are molecularly heterogeneous; however, a large fraction of testicular ENTs could be stratified by 2 distinct sets of genetic alterations, including MYCN/MYC amplification with concurrent suppression of the p53 pathway, and activation of the PI3K pathway with co-occurring CDK4 amplification. Moreover, the novel gene fusions identified in a subset of testicular GCT-derived ENTs overlap with molecularly defined tumors of embryonic-type neuroectodermal features in the central nervous system, indicating the potential common driving events for tumorigenesis from different anatomical sites.
Insights
Embryonic-type neuroectodermal tumors (ENTs) from testicular germ cell tumors (GCTs) show distinct molecular profiles. Genomic analysis reveals two main subtypes: one with MYCN/MYC amplification and p53 pathway inactivation, the other with PI3K pathway activation.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Embryonic-type neuroectodermal tumors (ENTs) are a somatic transformation of testicular germ cell tumors (GCTs).
- These tumors have a poor prognosis and limited treatment options, especially upon recurrence or metastasis.
- Comprehensive genomic data on GCT-derived ENTs is scarce, hindering understanding of their development.
Purpose of the Study:
- To investigate the molecular features of testicular GCT-derived ENTs.
- To identify key genetic alterations driving the transformation from GCTs to ENTs.
- To stratify these tumors based on distinct molecular profiles.
Main Methods:
- Retrospective analysis of 10 testicular GCT-derived ENTs.
- Next-generation sequencing-based comprehensive genomic profiling.
- Central rereview of clinicopathological and genomic data.
Main Results:
- All tumors showed chromosome 12p gain, supporting GCT origin, with frequent KRAS, CCND2, and KMD5A coamplification.
- Two distinct molecular subtypes were identified: 1) MYCN/MYC amplification with p53 pathway inactivation (TP53 mutation or MDM2 amplification) in 30% of tumors, and 2) PI3K pathway activation (PIK3CA/PIK3CG mutations or PIK3C2B amplification) in 30%, sometimes with CDK4 amplification.
- Novel gene fusions (BRD4::MAU2, BCOR::CLIP2) and an ATRX rearrangement were detected in 30% of tumors.
- Tumors were microsatellite-stable with low tumor mutational burden.
Conclusions:
- Testicular GCT-derived ENTs are molecularly diverse but can be classified into two main genetic alteration groups.
- These findings highlight potential common tumorigenic events between ENTs from different anatomical sites.
- Further research into these molecular subtypes may lead to targeted therapeutic strategies.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014